Mechanism of Action

Based on the available evidence, NR (nicotinamide riboside) appears to function as a NAD+ (nicotinamide adenine dinucleotide) precursor that supports cellular energy metabolism and potentially influences various physiological processes.

The clinical trial evidence suggests NR works through NAD replenishment therapy, as indicated by the NADAPT study investigating its use in atypical Parkinsonism. This mechanism involves NR serving as a substrate for NAD+ biosynthesis, which is crucial for cellular energy production through mitochondrial respiration and various enzymatic processes.

The completed clinical trials examine NR's effects in combination with exercise therapy in hypertensive older adults and as a general exercise enhancer, suggesting the compound may work by supporting cellular energy metabolism during physical activity. This is consistent with NAD+'s role in mitochondrial function and energy production pathways.

One ongoing study is investigating NR's acute effects on sleep structure in healthy adults, which may indicate the compound influences circadian rhythm regulation or neurological processes, though the specific molecular mechanisms for these effects are not detailed in the available evidence.

Evidence limitations: The provided evidence lacks detailed molecular-level mechanistic data for NR. The search results primarily contain clinical trial titles without published results or mechanistic studies. The PubMed findings do not appear to contain relevant studies specifically examining NR's mechanism of action, making it difficult to provide comprehensive molecular-level details about how this compound works.

This information is for educational purposes only and should not be considered personalized medical advice. Consult with a healthcare professional before using any supplement or therapy.

Based on the available clinical trial evidence, nicotinamide riboside (NR) is being investigated for several therapeutic applications, though research remains in early phases.

Cardiovascular and Exercise Performance
The completed NEET Trial (NCT04112043) examined NR as an enhancer of exercise therapy in hypertensive older adults in a Phase 1 study. A separate completed trial (NCT04907110) investigated NR supplementation combined with exercise, though specific outcomes from these studies are not detailed in the available evidence.

Neurological Conditions
The most advanced application appears to be in neurodegeneration, with the ongoing NADAPT Study (NCT06162013) currently recruiting participants for a Phase 2 randomized, double-blind trial examining NAD replenishment therapy for atypical parkinsonism. This represents the highest phase trial identified for NR.

Sleep Disorders
A planned trial (NCT07284225) will examine acute effects of NR on sleep structure in healthy adults using polysomnography measurements, though this study has not yet begun recruiting.

Evidence Limitations
The clinical evidence for NR is notably limited. Only one Phase 2 trial was identified, with most investigations remaining in Phase 1 or observational stages. The completed trials lack published outcome data in the available evidence, making it difficult to assess clinical efficacy. The research spans diverse applications from cardiovascular health to neurodegeneration, but definitive therapeutic benefits have not been established based on the current evidence.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation.

Safety Profile of Nicotinamide Riboside (NR)

Note: This information is for educational purposes only and is not intended as personalized medical advice. Consult with a healthcare provider before starting any supplement regimen.

Current Safety Evidence

The available evidence for NR safety is limited, based on a small number of clinical trials with relatively short durations. Most safety data comes from Phase 1 and early-phase studies in specific populations.

Known Side Effects

Evidence is thin regarding comprehensive side effect profiles for NR. The completed clinical trials (NCT04907110, NCT04112043) focusing on exercise enhancement and hypertensive older adults have not yet provided publicly available detailed safety data.

Common side effects reported in other NAD+ precursor studies have included:

• Gastrointestinal symptoms (nausea, stomach discomfort)
• Flushing
• Fatigue

However, specific side effect frequencies and severity for NR are not well-established in the current evidence base.

Contraindications

No specific contraindications are clearly established in the available evidence. The recruiting Phase 2 trial for atypical Parkinsonism (NCT06162013) and other studies suggest ongoing investigation in various disease states, but definitive contraindications have not been published.

Drug Interactions

Drug interaction data is extremely limited. The evidence provided does not include comprehensive interaction studies. Given NR's role as a NAD+ precursor and potential effects on cellular metabolism, theoretical interactions may exist with:

• Medications affecting cellular energy metabolism
• Cancer treatments (one suspended trial involved combination therapy)

However, specific interaction profiles require further research.

Populations That Should Exercise Caution

Based on the limited trial evidence:

Insufficient data exists for safety recommendations in:

• Pregnant or breastfeeding women
• Children and adolescents
• Individuals with severe liver or kidney disease
• Cancer patients (one cancer-related trial was suspended, though reasons are unclear)

Evidence Limitations

The safety evidence for NR is notably thin. Most trials are either ongoing, recently completed without published results, or focus on efficacy rather than comprehensive safety profiles. Long-term safety data is particularly lacking, and most studies have been conducted in relatively healthy populations or specific disease groups.

Recommendation: Given the limited safety data, individuals considering NR supplementation should consult with healthcare providers, especially those with pre-existing medical conditions or taking medications.

Research Papers and Clinical Trials

The available evidence for NR (nicotinamide riboside) research is currently limited, with only a handful of completed and ongoing clinical trials identified.

Clinical Trials:

The most relevant completed study is the NEET Trial (NCT04112043), a Phase 1 investigation examining nicotinamide riboside as an enhancer of exercise therapy in hypertensive older adults. Another completed trial (NCT04907110) studied NR supplementation in combination with exercise, though specific design details are not available from the current evidence.

Currently recruiting is the NADAPT Study (NCT06162013), a randomized double-blind Phase 2 trial investigating NAD replenishment therapy for atypical parkinsonism. An upcoming study (NCT07284225) plans to examine the acute effects of nicotinamide riboside on sleep structure in healthy adults using polysomnography measurements, though recruitment has not yet begun.

Research Papers:

The provided PubMed search results do not contain studies directly investigating nicotinamide riboside. One paper mentions "NR/EUG blends" (PMID: 42444337) but appears to focus on material science applications involving natural rubber compounds rather than the NAD+ precursor supplement.

Limitations:

The current evidence base for NR supplementation appears sparse, with most clinical trials either still in progress or providing limited publicly available data. The lack of published research papers specifically examining nicotinamide riboside in the provided search results suggests that comprehensive clinical evidence may be limited at this time.

This synthesis is based solely on the evidence provided and should not be considered personalized medical advice. Consult healthcare providers for individual treatment decisions.

Protocols

The available evidence provides limited information about specific dosing and administration protocols for NR (nicotinamide riboside). Based on the clinical trials identified in the literature search, several studies have investigated NR supplementation, but detailed protocol information is not provided in these search results.

The completed and ongoing trials include:

• Exercise-related studies: Two completed trials examined NR supplementation in combination with exercise therapy, including one focused on hypertensive older adults (NCT04112043, Phase 1) and another general exercise supplementation study (NCT04907110).

• Neurological applications: One ongoing Phase 2 trial (NCT06162013) is investigating NAD replenishment therapy for atypical Parkinsonism.

• Sleep research: One planned study (NCT07284225) will examine acute effects of NR on sleep structure in healthy adults.

However, the search results do not contain the actual dosing regimens, administration schedules, or specific protocols used in these studies. The abstracts and trial listings available do not provide sufficient detail about:

• Specific dosages tested
• Duration of treatment
• Frequency of administration
• Route of administration
• Patient selection criteria
• Monitoring requirements

Important Disclaimer: This information is provided for educational purposes only and represents a limited review of available literature. This is not personalized medical advice. Any decisions regarding NR supplementation should be made in consultation with qualified healthcare providers who can assess individual medical history, current medications, and specific health needs.

To obtain detailed protocol information, access to the full study publications or trial protocols would be necessary.

Outcomes

The available evidence on nicotinamide riboside (NR) outcomes is limited, with most data coming from small clinical trials that are either completed without published results or still recruiting participants.

Completed Studies

Exercise and Hypertension: One completed Phase 1 trial (NCT04112043) examined NR as an enhancer of exercise therapy in hypertensive older adults, but results have not been published or made available through the clinical trial registry.

Exercise Supplementation: Another completed study (NCT04907110) investigated NR supplementation in the context of exercise, but similarly lacks published outcome data.

Ongoing Research

Atypical Parkinsonism: A Phase 2 randomized, double-blind trial (NCT06162013) is currently recruiting participants to study NAD replenishment therapy for atypical Parkinsonism. This represents the most advanced clinical investigation identified, but no outcomes are yet available.

Sleep Effects: A planned study (NCT07284225) will examine acute effects of NR on sleep structure using polysomnography in healthy adults, but recruitment has not yet begun.

Evidence Limitations

The current evidence base for NR outcomes is notably weak. No measurable results, biomarker changes, or symptom improvements have been reported in the available literature searches. The PubMed findings did not yield any studies specifically examining NR therapeutic effects, and the completed clinical trials have not published their results.

Disclaimer: This summary is for informational purposes only and should not be used for medical decision-making. Consult with healthcare professionals for personalized medical advice regarding any treatment considerations.